Healthcare provider profile · identity verified

John Peter Serlemitsos, MD

Internal Medicine · CROWNSVILLE, MD · NPI 1861405367

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	306	38
Amlodipine Besylate	Amlodipine Besylate	254	28
Levothyroxine Sodium	Levothyroxine Sodium	139	18
Mirtazapine	Mirtazapine	123	15
Donepezil Hcl	Donepezil Hcl	116	13
Memantine Hcl	Memantine Hcl	114	14
Escitalopram Oxalate	Escitalopram Oxalate	105	11
Eliquis	Apixaban	100	17
Metformin Hcl	Metformin Hcl	95	12
Famotidine	Famotidine	90	12
Metoprolol Succinate	Metoprolol Succinate	89	12
Potassium Chloride	Potassium Chloride	87	11
Gabapentin	Gabapentin	84	11
Pantoprazole Sodium	Pantoprazole Sodium	82	12
Quetiapine Fumarate	Quetiapine Fumarate	82	12
Furosemide	Furosemide	81	14
Olanzapine	Olanzapine	76	suppressed
Trazodone Hcl	Trazodone Hcl	74	14
Metoprolol Tartrate	Metoprolol Tartrate	72	suppressed
Alendronate Sodium	Alendronate Sodium	71	suppressed
Losartan Potassium	Losartan Potassium	69	13
Clopidogrel	Clopidogrel Bisulfate	65	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	65	suppressed
Risperidone	Risperidone	65	suppressed
Levetiracetam	Levetiracetam	59	suppressed
Omeprazole	Omeprazole	54	suppressed
Simvastatin	Simvastatin	54	suppressed
Hydralazine Hcl	Hydralazine Hcl	47	suppressed
Digoxin	Digoxin	45	suppressed
Carvedilol	Carvedilol	44	suppressed
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	39	suppressed
Sertraline Hcl	Sertraline Hcl	36	suppressed
Lamotrigine	Lamotrigine	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	32	suppressed
Glipizide Er	Glipizide	32	suppressed
Montelukast Sodium	Montelukast Sodium	31	suppressed
Nifedipine Er	Nifedipine	30	suppressed
Xarelto	Rivaroxaban	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Glipizide	Glipizide	23	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Latanoprost	Latanoprost	21	suppressed
Lisinopril	Lisinopril	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Indapamide	Indapamide	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	11
Prednisone	Prednisone	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Amantadine	Amantadine Hcl	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Benztropine Mesylate	Benztropine Mesylate	14	suppressed
Clotrimazole	Clotrimazole	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	13	suppressed
Baclofen	Baclofen	13	suppressed
Colchicine	Colchicine	13	suppressed
Donepezil Hcl Odt	Donepezil Hcl	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Oxcarbazepine	Oxcarbazepine	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Clonidine	Clonidine	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Lactulose	Lactulose	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error